February 25, 2011 – The U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance for new radiotherapy treatment planning and delivery software. The software, from ViewRay, is a critical component of the company’s radiation therapy system, which combines simultaneous magnetic resonance imaging (MRI) and radiotherapy delivery.
The company is working to secure FDA clearance for commercial distribution of the system for clinical use.
The ViewRay system is being designed to provide continuous soft-tissue MRI during cancer treatment so that clinicians can see precisely where the radiation is being delivered. The company holds the exclusive worldwide license for its combination of MRI and radiotherapy technologies.
For more information: www.viewray.com
August 20, 2026 
